<DOC>
	<DOCNO>NCT02141165</DOCNO>
	<brief_summary>Primary objective : To determine efficacy cost-effectiveness management program patient obstructive sleep apnea syndrome ( OSAS ) carry primary specialist healthcare . In primary arm , diagnosis therapeutic decision make mean domiciliary nasal pressure ( DNP ) channel oximetry specialist healthcare arm use polysomnography ( PSG ) hospital . Patients intermediate-high suspicion OSAS include , take primary variable Epworth scale , efficacy , Epworth scale EuroQol 5D , cost-effectiveness . Secondary objective : efficacy two SAHS management program accord follow secondary variable : ) quality-of-life test : FOSQ questionnaire , SF36 analogical wellbeing scale , b ) adherence compliance treatment .</brief_summary>
	<brief_title>Home Nasal Pressure Sleep Apnea Management Primary Case</brief_title>
	<detailed_description>Design : prospective , randomize , control , open , parallel , non-inferiority . A total 280 patient randomized management basis DNP ( primary ) PSG ( specialist ) , thereby give rise 4 group : two treat two treated CPAP . The former undergo home auto-titration . The follow-up last 6 month include 4 evaluation .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>1 . Snoring apneas objectively observed sleep partner ; 2 . Symptoms potentially secondary apneas/hypopneas intermediatehigh probability treat CPAP . In operative term , Epworth scale â‰¥12 previous cardiovascular disease ; 3 . Age 18 70 year ; 4 . Absence clinical suspicion sleep pathology susceptible coinciding daytime sleepiness . 1 . Psychophysical incapacity complete questionnaire ; 2 . Documented structural coronary heart disease uncontrolled medical treatment ; 3 . CheyneStokes syndrome ; 4 . Patients subject uvulopalatopharyngoplasty ; 5 . Significant nasal obstruction impede use CPAP ; 6 . Pregnancy ; 7 . Lack informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>sleep apnea</keyword>
	<keyword>portable monitor</keyword>
	<keyword>primary care</keyword>
	<keyword>cost-effectiveness</keyword>
	<keyword>OSAS</keyword>
</DOC>